Skip to content
DataLookout
Menu

NCT07227909

NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy

StatusSuspended
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 12 versions: 5 with changes below, 7 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial status changed: Not Yet Recruiting → Suspended Sponsor's reason: PI Request
  2. Minor Enrollment target: 83 to 90
  3. Notable Eligibility criteria expanded, about 74 words
    • Study description expanded, about 5 words
  4. Notable Start date: May 4, 2026 to Nov 4, 2026v4
  5. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Safety and adverse events (AEs)
Timeframe: Through study completion; an average of 1 year

Arms and interventions

Arm AExperimental

Two supervised oral doses 1 week apart prior to chemotherapy cycle 1 (Day 7 and Day 14), followed by two monthly supervised doses prior to chemotherapy cycles 2 and 3 (Day 42 and Day 70); total 4 doses.

Arm BExperimental

Subperceptual dosing every other day for 2 weeks during the pre-chemotherapy run-in (mailed 7×1 mg capsules in tamperevident packaging) prior to the first three cycles as above (21 total doses)

Arm CExperimental

Standard of Care: Chemotherapy and supportive care per institutional guidelines; no study drug.

Drugs: Psilocybin (drug)

Other: Standard of Care (SOC)

Sites

1 site in 1 country

  • MD Anderson Cancer CenterHouston, Texas, United States